Sarepta Therapeutics Inc (NASDAQ:SRPT) – Investment analysts at Leerink Swann issued their FY2020 earnings per share estimates for shares of Sarepta Therapeutics in a research report issued on Thursday. Leerink Swann analyst J. Schwartz expects that the biotechnology company will post earnings per share of $2.91 for the year. Leerink Swann currently has a “Outperform” rating and a $77.00 price target on the stock.
A number of other analysts have also recently weighed in on the company. Barclays reaffirmed a “hold” rating and issued a $55.00 price target on shares of Sarepta Therapeutics in a research report on Tuesday. William Blair reaffirmed an “outperform” rating on shares of Sarepta Therapeutics in a research report on Monday, October 2nd. Zacks Investment Research cut Sarepta Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 5th. Robert W. Baird reaffirmed an “outperform” rating and issued a $101.00 price target on shares of Sarepta Therapeutics in a research report on Monday, October 2nd. Finally, UBS Group reaffirmed an “outperform” rating and issued a $56.51 price target (down previously from $76.00) on shares of Sarepta Therapeutics in a research report on Wednesday, December 27th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and eighteen have assigned a buy rating to the company’s stock. Sarepta Therapeutics has a consensus rating of “Buy” and an average price target of $64.65.
Sarepta Therapeutics (SRPT) traded up $1.37 on Monday, reaching $67.02. The company had a trading volume of 1,819,743 shares, compared to its average volume of 1,750,000. The firm has a market capitalization of $4,330.00, a PE ratio of -32.85 and a beta of 1.37. Sarepta Therapeutics has a 52-week low of $26.26 and a 52-week high of $67.74. The company has a current ratio of 10.44, a quick ratio of 9.52 and a debt-to-equity ratio of 0.04.
Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.66. The firm had revenue of $45.95 million during the quarter, compared to analysts’ expectations of $41.29 million. Sarepta Therapeutics had a negative return on equity of 51.72% and a negative net margin of 112.08%. During the same quarter last year, the firm earned ($0.95) earnings per share.
In related news, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the business’s stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $55.89, for a total transaction of $372,618.63. Following the completion of the transaction, the director now owns 13,333 shares of the company’s stock, valued at approximately $745,181.37. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Shamim Ruff sold 10,000 shares of the business’s stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $55.00, for a total value of $550,000.00. Following the transaction, the senior vice president now directly owns 37,045 shares of the company’s stock, valued at approximately $2,037,475. The disclosure for this sale can be found here. 9.60% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of SRPT. Ameritas Investment Partners Inc. lifted its position in shares of Sarepta Therapeutics by 6.3% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,561 shares of the biotechnology company’s stock worth $154,000 after purchasing an additional 271 shares during the last quarter. Cubist Systematic Strategies LLC increased its stake in Sarepta Therapeutics by 116.4% during the second quarter. Cubist Systematic Strategies LLC now owns 4,600 shares of the biotechnology company’s stock valued at $155,000 after acquiring an additional 2,474 shares during the period. Ladenburg Thalmann Financial Services Inc. increased its stake in Sarepta Therapeutics by 140.9% during the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,262 shares of the biotechnology company’s stock valued at $193,000 after acquiring an additional 2,493 shares during the period. Fox Run Management L.L.C. bought a new position in Sarepta Therapeutics during the third quarter valued at about $204,000. Finally, Bayesian Capital Management LP bought a new position in Sarepta Therapeutics during the second quarter valued at about $206,000. 81.97% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: This report was first posted by TrueBlueTribune and is the property of of TrueBlueTribune. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://www.truebluetribune.com/2018/01/23/fy2020-earnings-estimate-for-sarepta-therapeutics-inc-srpt-issued-by-leerink-swann.html.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.